<li>aceclofenac<p>aceclofenac increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>acemetacin<p>acemetacin increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>albiglutide<p>albiglutide, glimepiride.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Serious hypoglycemia may occur when insulin secretagogues and GLP-1 agonists are concurrently administered. Consider lowering the dose of insulin secretagogue to reduce the risk of hypoglycemia. .</p></li><li>alogliptin<p>alogliptin, glimepiride.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of alogliptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue .</p></li><li>aripiprazole<p>aripiprazole, glimepiride. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>asenapine<p>asenapine, glimepiride. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>aspirin<p>aspirin increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>aspirin rectal<p>aspirin rectal increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>atazanavir<p>atazanavir decreases effects of glimepiride by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>benazepril<p>benazepril increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects.</p></li><li>bexarotene<p>bexarotene increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor. Based on the mechanism of action, bexarotene capsules may increase the action of insulin enhancing agents, resulting in hypoglycemia. Hypoglycemia has not been associated with bexarotene monotherapy.</p></li><li>bezafibrate<p>bezafibrate increases effects of glimepiride by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>bitter melon<p>bitter melon increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>canagliflozin<p>glimepiride, canagliflozin.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.</p></li><li>captopril<p>captopril increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood glucose. Monitor blood glucose.</p></li><li>celecoxib<p>celecoxib increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>cholic acid<p>glimepiride increases toxicity of cholic acid by decreasing elimination. Modify Therapy/Monitor Closely. Avoid concomitant use of inhibitors of the bile salt efflux pump (BSEP). May exacerbate accumulation of conjugated bile salts in the liver and result in clinical symptoms. If concomitant use is necessary, monitor serum transaminases and bilirubin.</p></li><li>choline magnesium trisalicylate<p>choline magnesium trisalicylate increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>cinnamon<p>cinnamon increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor. Potential for hypoglycemia.</p></li><li>ciprofibrate<p>ciprofibrate increases effects of glimepiride by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>ciprofloxacin<p>ciprofloxacin increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor. Hyper and hypoglycemia have been reported in patients treated concomitantly with quinolones and antidiabetic agents. Careful monitoring of blood glucose is recommended.</p></li><li>clarithromycin<p>clarithromycin increases levels of glimepiride by plasma protein binding competition. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>clotrimazole<p>clotrimazole increases levels of glimepiride by decreasing metabolism. Use Caution/Monitor.</p></li><li>clozapine<p>clozapine, glimepiride. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>colesevelam<p>colesevelam decreases levels of glimepiride by drug binding in GI tract. Use Caution/Monitor. Concomitant administration decreases glimepiride absorption; however, absorption is not reduced when glimepiride is administered 4 hr before colesevelam.</p></li><li>dapagliflozin<p>glimepiride, dapagliflozin.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with dapagliflozin.</p></li><li>darunavir<p>darunavir decreases effects of glimepiride by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>diclofenac<p>diclofenac increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>diflunisal<p>diflunisal increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>disopyramide<p>disopyramide increases effects of glimepiride by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>dulaglutide<p>dulaglutide, glimepiride.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df decreases levels of glimepiride by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Elvitegravir is a moderate CYP2C9 inducer.</p></li><li>empagliflozin<p>empagliflozin, glimepiride.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with SGLT2 inhibitors.</p></li><li>enalapril<p>enalapril increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>etodolac<p>etodolac increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>etoricoxib<p>etoricoxib increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>exenatide injectable solution<p>exenatide injectable solution, glimepiride.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypoglycemia when exenatide is used in combination with agents that induce hypoglycemia. Consider lowering dose of sulfonylureas to reduce risk of hypoglycemia. .</p></li><li>exenatide injectable suspension<p>exenatide injectable suspension, glimepiride.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypoglycemia when exenatide is used in combination with agents that induce hypoglycemia. Consider lowering dose of sulfonylureas to reduce risk of hypoglycemia.</p></li><li>fenbufen<p>fenbufen increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>fenofibrate<p>fenofibrate increases effects of glimepiride by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>fenofibrate micronized<p>fenofibrate micronized increases effects of glimepiride by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>fenofibric acid<p>fenofibric acid increases effects of glimepiride by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>fenoprofen<p>fenoprofen increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>fleroxacin<p>fleroxacin increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>fluconazole<p>fluconazole increases levels of glimepiride by decreasing metabolism. Use Caution/Monitor.</p></li><li>fluoxetine<p>fluoxetine increases effects of glimepiride by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>flurbiprofen<p>flurbiprofen increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>fosamprenavir<p>fosamprenavir decreases effects of glimepiride by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>fosinopril<p>fosinopril increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>gemfibrozil<p>gemfibrozil increases effects of glimepiride by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>gemifloxacin<p>gemifloxacin increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>ibuprofen<p>ibuprofen increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>iloperidone<p>iloperidone, glimepiride. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>imidapril<p>imidapril increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>indinavir<p>indinavir decreases effects of glimepiride by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>indomethacin<p>indomethacin increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>insulin aspart<p>glimepiride, insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin aspart protamine/insulin aspart<p>glimepiride, insulin aspart protamine/insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin degludec<p>glimepiride, insulin degludec.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin degludec/insulin aspart<p>glimepiride, insulin degludec/insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin detemir<p>glimepiride, insulin detemir.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin glargine<p>glimepiride, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin glulisine<p>glimepiride, insulin glulisine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin inhaled<p>glimepiride, insulin inhaled.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin isophane human/insulin regular human<p>glimepiride, insulin isophane human/insulin regular human.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin lispro<p>glimepiride, insulin lispro.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin lispro protamine/insulin lispro<p>glimepiride, insulin lispro protamine/insulin lispro.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin nph<p>glimepiride, insulin nph.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>insulin regular human<p>glimepiride, insulin regular human.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>isocarboxazid<p>isocarboxazid increases effects of glimepiride by unknown mechanism. Use Caution/Monitor.</p></li><li>itraconazole<p>itraconazole increases levels of glimepiride by decreasing metabolism. Use Caution/Monitor.</p></li><li>ketoconazole<p>ketoconazole increases levels of glimepiride by decreasing metabolism. Use Caution/Monitor.</p></li><li>ketoprofen<p>ketoprofen increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>ketorolac<p>ketorolac increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>ketorolac intranasal<p>ketorolac intranasal increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>ketotifen, ophthalmic<p>ketotifen, ophthalmic, glimepiride. Other (see comment). Use Caution/Monitor. 
Comment: Combination may result in thrombocytopenia (rare).  Monitor CBC.</p></li><li>levofloxacin<p>levofloxacin increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>linagliptin<p>glimepiride, linagliptin. Other (see comment). Use Caution/Monitor. 
Comment: When linagliptin is used in combination with sulfonylureas, a lower dose of the sulfonylurea may be required to reduce risk of hypoglycemia.</p></li><li>linezolid<p>linezolid increases effects of glimepiride by unknown mechanism. Use Caution/Monitor.</p></li><li>liraglutide<p>liraglutide, glimepiride.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Serious hypoglycemia may occur when insulin secretagogues and GLP-1 agonists are concurrently administered. Consider lowering the dose of insulin secretagogue to reduce the risk of hypoglycemia. .</p></li><li>lisinopril<p>lisinopril increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>lixisenatide<p>lixisenatide, glimepiride.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Risk of hypoglycemia increased when coadministered with sulfonylureas. Sulfonylurea dosage reduction may be required.</p></li><li>lopinavir<p>lopinavir decreases effects of glimepiride by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>lornoxicam<p>lornoxicam increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>lurasidone<p>lurasidone, glimepiride. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>marijuana<p>marijuana decreases effects of glimepiride by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>mecasermin<p>mecasermin increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects.</p></li><li>meclofenamate<p>meclofenamate increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>mefenamic acid<p>mefenamic acid increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>meloxicam<p>meloxicam increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>metreleptin<p>glimepiride, metreleptin.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue.</p></li><li>miconazole vaginal<p>miconazole vaginal increases levels of glimepiride by decreasing metabolism. Use Caution/Monitor.</p></li><li>mipomersen<p>mipomersen, glimepiride.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.</p></li><li>moexipril<p>moexipril increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>moxifloxacin<p>moxifloxacin increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>nabumetone<p>nabumetone increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>nadolol<p>nadolol decreases effects of glimepiride by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.</p></li><li>naproxen<p>naproxen increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>nelfinavir<p>nelfinavir decreases effects of glimepiride by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>nitisinone<p>nitisinone will increase the level or effect of glimepiride by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index.</p></li><li>norfloxacin<p>norfloxacin increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>ofloxacin<p>ofloxacin increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>olanzapine<p>olanzapine, glimepiride. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>opuntia ficus indica<p>opuntia ficus indica increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>oxaprozin<p>oxaprozin increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>paliperidone<p>paliperidone, glimepiride. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>parecoxib<p>parecoxib increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>peginterferon alfa 2b<p>peginterferon alfa 2b decreases levels of glimepiride by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered. .</p></li><li>perindopril<p>perindopril increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>phenelzine<p>phenelzine increases effects of glimepiride by unknown mechanism. Use Caution/Monitor.</p></li><li>pindolol<p>pindolol decreases effects of glimepiride by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.</p></li><li>piroxicam<p>piroxicam increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>posaconazole<p>posaconazole increases levels of glimepiride by decreasing metabolism. Use Caution/Monitor.</p></li><li>probenecid<p>probenecid increases levels of glimepiride by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>propranolol<p>propranolol decreases effects of glimepiride by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.</p></li><li>quetiapine<p>quetiapine, glimepiride. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>quinapril<p>quinapril increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>ramipril<p>ramipril increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>rifabutin<p>rifabutin decreases levels of glimepiride by increasing metabolism. Use Caution/Monitor.</p></li><li>rifampin<p>rifampin decreases levels of glimepiride by increasing metabolism. Use Caution/Monitor.</p></li><li>rifapentine<p>rifapentine decreases levels of glimepiride by increasing metabolism. Use Caution/Monitor.</p></li><li>risperidone<p>risperidone, glimepiride. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>ritonavir<p>ritonavir, glimepiride. Other (see comment). Use Caution/Monitor. 
Comment: Ritonavir may increase or decrease levels of glimepiride. Use alternatives if available. Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>salicylates (non-asa)<p>salicylates (non-asa) increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>salsalate<p>salsalate increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>saquinavir<p>saquinavir decreases effects of glimepiride by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>selegiline<p>selegiline increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Serum glucose should be monitored closely when MAOIs are added to any regimen containing antidiabetic medications. Hypoglycemic effects may be increased.</p></li><li>selegiline transdermal<p>selegiline transdermal increases effects of glimepiride by unknown mechanism. Use Caution/Monitor.</p></li><li>shark cartilage<p>shark cartilage increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor. Theoretical interaction.</p></li><li>sulfadiazine<p>sulfadiazine increases levels of glimepiride by plasma protein binding competition. Use Caution/Monitor.</p></li><li>sulfamethoxazole<p>sulfamethoxazole increases levels of glimepiride by plasma protein binding competition. Use Caution/Monitor.</p></li><li>sulfamethoxypyridazine<p>sulfamethoxypyridazine increases effects of glimepiride by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>sulfasalazine<p>sulfasalazine increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>sulfisoxazole<p>sulfisoxazole increases levels of glimepiride by plasma protein binding competition. Use Caution/Monitor.</p></li><li>sulindac<p>sulindac increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>timolol<p>timolol decreases effects of glimepiride by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.</p></li><li>tipranavir<p>tipranavir decreases effects of glimepiride by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>tolfenamic acid<p>tolfenamic acid increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>tolmetin<p>tolmetin increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>trandolapril<p>trandolapril increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>tranylcypromine<p>tranylcypromine increases effects of glimepiride by unknown mechanism. Use Caution/Monitor.</p></li><li>trimagnesium citrate anhydrous<p>trimagnesium citrate anhydrous increases levels of glimepiride by enhancing GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>voriconazole<p>voriconazole increases levels of glimepiride by decreasing metabolism. Use Caution/Monitor.</p></li><li>xipamide<p>xipamide decreases levels of glimepiride by increasing renal clearance. Use Caution/Monitor.</p></li><li>ziprasidone<p>ziprasidone, glimepiride. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li>